Effects of age on the glucose metabolic changes in mild cognitive impairment.
Effects of age on the glucose metabolic changes in mild cognitive impairment.
复制标题
DOI：
10.3174/ajnr.a2070
复制
发表时间：
2010-08
期刊：
影响因子：
--
通讯作者：
Jack CR Jr
中科院分区：
文献类型：
--
作者：
Kantarci K;Senjem ML;Lowe VJ;Wiste HJ;Weigand SD;Kemp BJ;Frank AR;Shiung MM;Boeve BF;Knopman DS;Petersen RC;Jack CR Jr
[18F]氟脱氧葡萄糖（FDG） PET显示的颞叶和顶叶糖代谢下降被认为是阿尔茨海默病（AD）病理的早期成像标志物。我们的目的是研究年龄对aMCI中FDG PET结果的影响。25例55-86岁aMCI患者（中位= 73）和25例年龄和性别匹配的认知正常（CN）受试者接受FDG PET检查。SPM5用于比较amci老年（bb0 73岁）和amci年轻（bb1 73岁）患者与CN受试者的FDG摄取。在年龄大于73岁的10名aMCI和13名CN患者的单独队列中，对aMCI老年患者的研究结果进行了独立验证。amci年轻受试者的内侧颞叶、扣带回后部、楔前叶、外侧顶叶和颞叶的糖代谢降低和灰质萎缩的模式与AD的典型模式一致。amci老年受试者的糖代谢变化模式不同，主要累及额叶和左顶叶。老年aMCI患者的灰质萎缩不像年轻aMCI患者那么明显，涉及两个半球的海马和基底前脑，病理异质性可能是老年aMCI患者与年轻aMCI患者相比缺乏ad样葡萄糖代谢变化的基础。这可能是临床使用FDG PET颞顶叶低代谢作为aMCI早期诊断AD的标志物的重要考虑因素。
Decreased glucose metabolism in the temporal and parietal lobes on [18F]fluorodeoxyglucose (FDG) PET is recognized as an early imaging marker for the Alzheimer’s disease (AD) pathology. Our objective was to investigate the effects of age on FDG PET findings in aMCI. 25 patients with aMCI at 55–86 years of age (median = 73), and 25 age and gender matched cognitively normal (CN) subjects underwent FDG PET. SPM5 was used to compare the FDG uptake in aMCI-old (>73 years) and aMCI-young (>73 years) patients to CN subjects. The findings in the aMCI-old patients were independently validated in a separate cohort of 10 aMCI and 13 CN subjects older than 73 years of age. The pattern of decreased glucose metabolism and gray matter atrophy in the medial temporal, posterior cingulate, precuneus, lateral parietal and temporal lobes in aMCI-young subjects was consistent with the typical pattern observed in AD. The pattern of glucose metabolic changes in aMCI-old subjects was different, predominantly involving the frontal lobes and the left parietal lobe. Gray matter atrophy in aMCI-old subjects was less pronounced than the aMCI-young subjects involving the hippocampus and the basal forebrain in both hemispheres Pathological heterogeneity may be underlying the absence of AD-like glucose metabolic changes in older compared to younger aMCI patients. This may be an important consideration for the clinical use of temporoparietal hypometabolism on FDG PET as a marker for early diagnosis of AD in aMCI.